Saleh A W, Hillen H F, Duits A J
Department of Internal Medicine, St. Elisabeth Hospital, Curaçao, The Netherlands Antilles.
Acta Haematol. 1999;102(1):31-7. doi: 10.1159/000040964.
It has been shown that the clinical course of sickle cell (SS) patients can be ameliorated by administration of hydroxyurea (HU). Induction of hemoglobin F (HbF) is thought to be the mechanism responsible for clinical improvement in some patients. However, HU has a variable effect on HbF production and there exists no good correlation between the extent of HbF increase and clinical response. On the other hand, the degree of adherence of SS to vascular endothelium and neutrophil counts correlate well with clinical severity. Being a cytotoxic drug, used in myeloproliferative diseases, HU may alter proliferation among various cell lines. Moreover, HU has been reported to reduce red blood cell (RBC) adhesion receptor expression in young SS individuals and induces changes in endothelial cells in vitro. It should be conceived that in addition to its effects on HbF production, HU may change the clinical symptoms of SS patients by affecting the degree of adherence of different blood cells, by influencing the activity of endothelium as well as the activity of white blood cells (WBC) and platelets. To analyze whether several of the determinants of adhesion are modulated by HU treatment we studied the levels of endothelial activity (soluble vascular adhesion molecule-1, (sVCAM-1), interleukin-8 (IL-8), fibronectin, neutrophil activity (sL-selectin, sIL-6 receptor-alpha, myeloperoxidase) and platelet activity (von Willebrand factor) in relation to clinical symptoms, hematological data and HbF levels in 8 SS patients before and during 5 months of HU therapy. Steady state sVCAM-1 levels are increased compared to normal controls and a significant decrease is noted during HU treatment, suggesting a decrease in the interactions between RBC and vascular endothelium. The IL-8 levels are comparable to those in normal controls and remain unaffected by HU therapy. Intercurrent infection and crises reveal striking increases in IL-8 which are accompanied by leukocytosis, but otherwise the IL-8 levels do not correlate with hematological data. HU has no demonstrable effect on fibronectin or soluble neutrophil adhesion molecules, but the levels of myeloperoxidase decrease significantly while WBC counts do not, implying a reduction in neutrophil activity which may help attenuate the propagation phase of a vasoocclusive crisis.
已表明,给予羟基脲(HU)可改善镰状细胞(SS)患者的临床病程。血红蛋白F(HbF)的诱导被认为是一些患者临床改善的机制。然而,HU对HbF产生的影响是可变的,HbF增加的程度与临床反应之间没有良好的相关性。另一方面,SS与血管内皮的粘附程度和中性粒细胞计数与临床严重程度密切相关。作为一种用于骨髓增殖性疾病的细胞毒性药物,HU可能会改变各种细胞系的增殖。此外,据报道,HU可降低年轻SS个体中红细胞(RBC)粘附受体的表达,并在体外诱导内皮细胞发生变化。应该想到,除了对HbF产生的影响外,HU可能通过影响不同血细胞的粘附程度、影响内皮活性以及白细胞(WBC)和血小板的活性来改变SS患者的临床症状。为了分析HU治疗是否调节了几种粘附决定因素,我们研究了8名SS患者在HU治疗前和治疗5个月期间内皮活性(可溶性血管粘附分子-1,(sVCAM-1)、白细胞介素-8(IL-8)、纤连蛋白)、中性粒细胞活性(sL-选择素、sIL-6受体-α、髓过氧化物酶)和血小板活性(血管性血友病因子)水平与临床症状、血液学数据和HbF水平的关系。与正常对照组相比,稳态sVCAM-1水平升高,并且在HU治疗期间显著降低,表明RBC与血管内皮之间的相互作用减少。IL-8水平与正常对照组相当,并且不受HU治疗的影响。并发感染和危象时IL-8显著增加,同时伴有白细胞增多,但除此之外,IL-8水平与血液学数据无关。HU对纤连蛋白或可溶性中性粒细胞粘附分子没有明显影响,但髓过氧化物酶水平显著降低,而白细胞计数没有降低,这意味着中性粒细胞活性降低,这可能有助于减轻血管闭塞性危象的传播阶段。